Immunome
Immunome is a biotechnology company focused on developing innovative cancer therapies, including immunotherapies and targeted treatments, using its proprietary memory B cell hybridoma technology.
Company Overview
Immunome is a company dedicated to developing first-in-class and best-in-class targeted cancer therapies. The company is headquartered at 18702 North Creek Parkway, Suite 100, Bothell, WA 98011. Leveraging advanced technology, Immunome aims to revolutionize cancer treatment through a diverse portfolio of innovative therapies.
Cancer Therapies by Immunome
Immunome's portfolio includes various advanced therapies for cancer treatment. These encompass immunotherapies, targeted effectors, radioligand therapies, and antibody drug conjugates (ADCs). By focusing on cutting-edge science, the company aims to provide effective treatments for various cancer types.
Proprietary Technology
Immunome utilizes a proprietary memory B cell hybridoma technology. This technology enables rapid screening and functional characterization of novel antibodies and targets. It is a critical component in the development of the company's diverse portfolio of cancer therapies.
IM-4320 Program
The lead program at Immunome, IM-4320, focuses on targeting IL-38, an immunosuppressive cytokine. This program aims to develop a potential treatment for cancer by modulating the immune environment. IM-4320 is a key asset in the company's strategic efforts to treat cancer effectively.
Radioligand Therapy Targeting Fibroblast Activation Protein (FAP)
Immunome is progressing with a Fibroblast Activation Protein (FAP) targeted radioligand therapy. This therapy has potential applications in over 75% of solid tumors. The development of this therapy highlights the company's focus on innovative cancer treatments with wide-reaching applicability.
Acquisition of AL102 for Desmoid Tumor Treatment
Immunome recently completed the acquisition of AL102 from Ayala. AL102 is a Phase 3 asset aimed at treating Desmoid Tumors. This acquisition is a strategic move to expand Immunome's capabilities and therapeutic offerings in the oncology sector.